IBDEI366 ; ; 04-FEB-2020
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,50611,2)
;;=^5007236
;;^UTILITY(U,$J,358.3,50612,0)
;;=I49.9^^193^2496^2
;;^UTILITY(U,$J,358.3,50612,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,50612,1,3,0)
;;=3^Cardiac Arrhythmia,Unspec
;;^UTILITY(U,$J,358.3,50612,1,4,0)
;;=4^I49.9
;;^UTILITY(U,$J,358.3,50612,2)
;;=^5007237
;;^UTILITY(U,$J,358.3,50613,0)
;;=R00.1^^193^2496^1
;;^UTILITY(U,$J,358.3,50613,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,50613,1,3,0)
;;=3^Bradycardia,Unspec
;;^UTILITY(U,$J,358.3,50613,1,4,0)
;;=4^R00.1
;;^UTILITY(U,$J,358.3,50613,2)
;;=^5019164
;;^UTILITY(U,$J,358.3,50614,0)
;;=I34.1^^193^2496^14
;;^UTILITY(U,$J,358.3,50614,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,50614,1,3,0)
;;=3^Nonrheumatic Mitral Valve Prolapse
;;^UTILITY(U,$J,358.3,50614,1,4,0)
;;=4^I34.1
;;^UTILITY(U,$J,358.3,50614,2)
;;=^5007170
;;^UTILITY(U,$J,358.3,50615,0)
;;=D68.4^^193^2497^1
;;^UTILITY(U,$J,358.3,50615,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,50615,1,3,0)
;;=3^Acquired Coagulation Factor Deficiency
;;^UTILITY(U,$J,358.3,50615,1,4,0)
;;=4^D68.4
;;^UTILITY(U,$J,358.3,50615,2)
;;=^2235
;;^UTILITY(U,$J,358.3,50616,0)
;;=D59.9^^193^2497^2
;;^UTILITY(U,$J,358.3,50616,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,50616,1,3,0)
;;=3^Acquired Hemolytic Anemia,Unspec
;;^UTILITY(U,$J,358.3,50616,1,4,0)
;;=4^D59.9
;;^UTILITY(U,$J,358.3,50616,2)
;;=^5002330
;;^UTILITY(U,$J,358.3,50617,0)
;;=C91.00^^193^2497^5
;;^UTILITY(U,$J,358.3,50617,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,50617,1,3,0)
;;=3^Acute Lymphoblastic Leukemia,Not in Remission
;;^UTILITY(U,$J,358.3,50617,1,4,0)
;;=4^C91.00
;;^UTILITY(U,$J,358.3,50617,2)
;;=^5001762
;;^UTILITY(U,$J,358.3,50618,0)
;;=C91.01^^193^2497^4
;;^UTILITY(U,$J,358.3,50618,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,50618,1,3,0)
;;=3^Acute Lymphoblastic Leukemia,In Remission
;;^UTILITY(U,$J,358.3,50618,1,4,0)
;;=4^C91.01
;;^UTILITY(U,$J,358.3,50618,2)
;;=^5001763
;;^UTILITY(U,$J,358.3,50619,0)
;;=C92.01^^193^2497^7
;;^UTILITY(U,$J,358.3,50619,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,50619,1,3,0)
;;=3^Acute Myeloblastic Leukemia,In Remission
;;^UTILITY(U,$J,358.3,50619,1,4,0)
;;=4^C92.01
;;^UTILITY(U,$J,358.3,50619,2)
;;=^5001790
;;^UTILITY(U,$J,358.3,50620,0)
;;=C92.00^^193^2497^8
;;^UTILITY(U,$J,358.3,50620,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,50620,1,3,0)
;;=3^Acute Myeloblastic Leukemia,Not in Remission
;;^UTILITY(U,$J,358.3,50620,1,4,0)
;;=4^C92.00
;;^UTILITY(U,$J,358.3,50620,2)
;;=^5001789
;;^UTILITY(U,$J,358.3,50621,0)
;;=C92.61^^193^2497^9
;;^UTILITY(U,$J,358.3,50621,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,50621,1,3,0)
;;=3^Acute Myeloid Leukemia w/ 11q23-Abnormality,In Remission
;;^UTILITY(U,$J,358.3,50621,1,4,0)
;;=4^C92.61
;;^UTILITY(U,$J,358.3,50621,2)
;;=^5001808
;;^UTILITY(U,$J,358.3,50622,0)
;;=C92.60^^193^2497^10
;;^UTILITY(U,$J,358.3,50622,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,50622,1,3,0)
;;=3^Acute Myeloid Leukemia w/ 11q23-Abnormality,Not in Remission
;;^UTILITY(U,$J,358.3,50622,1,4,0)
;;=4^C92.60
;;^UTILITY(U,$J,358.3,50622,2)
;;=^5001807
;;^UTILITY(U,$J,358.3,50623,0)
;;=C92.A1^^193^2497^11
;;^UTILITY(U,$J,358.3,50623,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,50623,1,3,0)
;;=3^Acute Myeloid Leukemia w/ Multilin Dysplasia,In Remission
;;^UTILITY(U,$J,358.3,50623,1,4,0)
;;=4^C92.A1
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI366 3784 printed Nov 22, 2024@17:52:43 Page 2
IBDEI366 ; ; 04-FEB-2020
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,50611,2)
+2 ;;=^5007236
+3 ;;^UTILITY(U,$J,358.3,50612,0)
+4 ;;=I49.9^^193^2496^2
+5 ;;^UTILITY(U,$J,358.3,50612,1,0)
+6 ;;=^358.31IA^4^2
+7 ;;^UTILITY(U,$J,358.3,50612,1,3,0)
+8 ;;=3^Cardiac Arrhythmia,Unspec
+9 ;;^UTILITY(U,$J,358.3,50612,1,4,0)
+10 ;;=4^I49.9
+11 ;;^UTILITY(U,$J,358.3,50612,2)
+12 ;;=^5007237
+13 ;;^UTILITY(U,$J,358.3,50613,0)
+14 ;;=R00.1^^193^2496^1
+15 ;;^UTILITY(U,$J,358.3,50613,1,0)
+16 ;;=^358.31IA^4^2
+17 ;;^UTILITY(U,$J,358.3,50613,1,3,0)
+18 ;;=3^Bradycardia,Unspec
+19 ;;^UTILITY(U,$J,358.3,50613,1,4,0)
+20 ;;=4^R00.1
+21 ;;^UTILITY(U,$J,358.3,50613,2)
+22 ;;=^5019164
+23 ;;^UTILITY(U,$J,358.3,50614,0)
+24 ;;=I34.1^^193^2496^14
+25 ;;^UTILITY(U,$J,358.3,50614,1,0)
+26 ;;=^358.31IA^4^2
+27 ;;^UTILITY(U,$J,358.3,50614,1,3,0)
+28 ;;=3^Nonrheumatic Mitral Valve Prolapse
+29 ;;^UTILITY(U,$J,358.3,50614,1,4,0)
+30 ;;=4^I34.1
+31 ;;^UTILITY(U,$J,358.3,50614,2)
+32 ;;=^5007170
+33 ;;^UTILITY(U,$J,358.3,50615,0)
+34 ;;=D68.4^^193^2497^1
+35 ;;^UTILITY(U,$J,358.3,50615,1,0)
+36 ;;=^358.31IA^4^2
+37 ;;^UTILITY(U,$J,358.3,50615,1,3,0)
+38 ;;=3^Acquired Coagulation Factor Deficiency
+39 ;;^UTILITY(U,$J,358.3,50615,1,4,0)
+40 ;;=4^D68.4
+41 ;;^UTILITY(U,$J,358.3,50615,2)
+42 ;;=^2235
+43 ;;^UTILITY(U,$J,358.3,50616,0)
+44 ;;=D59.9^^193^2497^2
+45 ;;^UTILITY(U,$J,358.3,50616,1,0)
+46 ;;=^358.31IA^4^2
+47 ;;^UTILITY(U,$J,358.3,50616,1,3,0)
+48 ;;=3^Acquired Hemolytic Anemia,Unspec
+49 ;;^UTILITY(U,$J,358.3,50616,1,4,0)
+50 ;;=4^D59.9
+51 ;;^UTILITY(U,$J,358.3,50616,2)
+52 ;;=^5002330
+53 ;;^UTILITY(U,$J,358.3,50617,0)
+54 ;;=C91.00^^193^2497^5
+55 ;;^UTILITY(U,$J,358.3,50617,1,0)
+56 ;;=^358.31IA^4^2
+57 ;;^UTILITY(U,$J,358.3,50617,1,3,0)
+58 ;;=3^Acute Lymphoblastic Leukemia,Not in Remission
+59 ;;^UTILITY(U,$J,358.3,50617,1,4,0)
+60 ;;=4^C91.00
+61 ;;^UTILITY(U,$J,358.3,50617,2)
+62 ;;=^5001762
+63 ;;^UTILITY(U,$J,358.3,50618,0)
+64 ;;=C91.01^^193^2497^4
+65 ;;^UTILITY(U,$J,358.3,50618,1,0)
+66 ;;=^358.31IA^4^2
+67 ;;^UTILITY(U,$J,358.3,50618,1,3,0)
+68 ;;=3^Acute Lymphoblastic Leukemia,In Remission
+69 ;;^UTILITY(U,$J,358.3,50618,1,4,0)
+70 ;;=4^C91.01
+71 ;;^UTILITY(U,$J,358.3,50618,2)
+72 ;;=^5001763
+73 ;;^UTILITY(U,$J,358.3,50619,0)
+74 ;;=C92.01^^193^2497^7
+75 ;;^UTILITY(U,$J,358.3,50619,1,0)
+76 ;;=^358.31IA^4^2
+77 ;;^UTILITY(U,$J,358.3,50619,1,3,0)
+78 ;;=3^Acute Myeloblastic Leukemia,In Remission
+79 ;;^UTILITY(U,$J,358.3,50619,1,4,0)
+80 ;;=4^C92.01
+81 ;;^UTILITY(U,$J,358.3,50619,2)
+82 ;;=^5001790
+83 ;;^UTILITY(U,$J,358.3,50620,0)
+84 ;;=C92.00^^193^2497^8
+85 ;;^UTILITY(U,$J,358.3,50620,1,0)
+86 ;;=^358.31IA^4^2
+87 ;;^UTILITY(U,$J,358.3,50620,1,3,0)
+88 ;;=3^Acute Myeloblastic Leukemia,Not in Remission
+89 ;;^UTILITY(U,$J,358.3,50620,1,4,0)
+90 ;;=4^C92.00
+91 ;;^UTILITY(U,$J,358.3,50620,2)
+92 ;;=^5001789
+93 ;;^UTILITY(U,$J,358.3,50621,0)
+94 ;;=C92.61^^193^2497^9
+95 ;;^UTILITY(U,$J,358.3,50621,1,0)
+96 ;;=^358.31IA^4^2
+97 ;;^UTILITY(U,$J,358.3,50621,1,3,0)
+98 ;;=3^Acute Myeloid Leukemia w/ 11q23-Abnormality,In Remission
+99 ;;^UTILITY(U,$J,358.3,50621,1,4,0)
+100 ;;=4^C92.61
+101 ;;^UTILITY(U,$J,358.3,50621,2)
+102 ;;=^5001808
+103 ;;^UTILITY(U,$J,358.3,50622,0)
+104 ;;=C92.60^^193^2497^10
+105 ;;^UTILITY(U,$J,358.3,50622,1,0)
+106 ;;=^358.31IA^4^2
+107 ;;^UTILITY(U,$J,358.3,50622,1,3,0)
+108 ;;=3^Acute Myeloid Leukemia w/ 11q23-Abnormality,Not in Remission
+109 ;;^UTILITY(U,$J,358.3,50622,1,4,0)
+110 ;;=4^C92.60
+111 ;;^UTILITY(U,$J,358.3,50622,2)
+112 ;;=^5001807
+113 ;;^UTILITY(U,$J,358.3,50623,0)
+114 ;;=C92.A1^^193^2497^11
+115 ;;^UTILITY(U,$J,358.3,50623,1,0)
+116 ;;=^358.31IA^4^2
+117 ;;^UTILITY(U,$J,358.3,50623,1,3,0)
+118 ;;=3^Acute Myeloid Leukemia w/ Multilin Dysplasia,In Remission
+119 ;;^UTILITY(U,$J,358.3,50623,1,4,0)
+120 ;;=4^C92.A1
